Beta Bionics
BBNX
133 hedge funds and large institutions have $752M invested in Beta Bionics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 56 increasing their positions, 35 reducing their positions, and 23 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 35
52% more capital invested
Capital invested by funds: $495M → $752M (+$258M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
2% more funds holding
Funds holding: 130 → 133 (+3)
4.39% less ownership
Funds ownership: 112.04% → 107.65% (-4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$13.2M |
| 2 |
TLP
Tri Locum Partners
New York
|
+$5.87M |
| 3 |
Goldman Sachs
New York
|
+$4.94M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$4.88M |
| 5 |
JP Morgan Chase
New York
|
+$4.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$35.8M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$7.27M |
| 3 |
RI
RTW Investments
New York
|
-$5.95M |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$5.03M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.22M |
BBNX Hedge Fund Activity: Q2 2026 in Review
133 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Beta Bionics (BBNX) for Q2 2026, worth a combined $752M — up 52% from $495M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BBNX positions and 23 closed out — a net gain of 6 holders — while 56 added to existing stakes and 35 trimmed.
The largest buyer was Divisadero Street Capital Management, opening a new position worth an estimated $13.2M. The largest seller was Farallon Capital Management, cutting an estimated $35.8M.
- 133 institutional investors held Beta Bionics (BBNX) as of Q2 2026, up from 130 in Q1 2026.
- Funds reported $752M of Beta Bionics stock for Q2 2026, up 52% quarter-over-quarter.
- 29 funds opened new Beta Bionics positions in Q2 2026 and 23 closed out, a net change of +6 holders.
- The largest Beta Bionics buyer in Q2 2026 was Divisadero Street Capital Management, an estimated $13.2M added.
- The largest Beta Bionics seller in Q2 2026 was Farallon Capital Management, an estimated $35.8M sold.
Based on aggregated 13F filings for Q2 2026.